AOD-9604 in Hiragi — Fat Loss Peptide Research Guide
AOD-9604 research guide for Hiragi. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Hiragi looking to source AOD-9604, the foundational reality is that this compound is available only through an online research supply market. What this means for Hiragi researchers is that your location matters far less than your ability to assess COA data — and those verification methods are accessible to anyone. What genuinely separates top AOD-9604 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety screening. This guide walks Hiragi researchers through that evaluation process and explains how to verify AOD-9604 vendor quality step by step.
What Studies Say About AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Hiragi comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Where to Buy AOD-9604 — A Researcher's Guide
Before assessing any particular supplier, build a clear picture of what a proper COA looks like — so you can identify whether a supplier meets the standard. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from microbial contamination can trigger dangerous inflammatory cascades even at minute levels. For Hiragi researchers evaluating new suppliers: a modest first purchase to test the product before scaling up your order is the accepted approach among experienced researchers. Hold lyophilised AOD-9604 at −20°C until ready to use; reconstitute only the quantity required for your immediate research and keep the remainder frozen.
Order AOD-9604 — ships to Hiragi
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and restricted human research data. Reconstitute AOD-9604 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — providing 25mcg per unit measured on a 100-unit syringe. The primary quality-related safety risk in AOD-9604 research is bacterial endotoxin from low-quality material — a documented endotoxin result in your specific batch certificate is the specific protection against this risk. Researchers running multi-compound protocols with AOD-9604 should check the research literature for any reported interactions before running stacked compound experiments.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
